Medicare will keep covering popular glucagon-like peptide-1 drugs through the end of 2027, the Centers for Medicare and Medicaid Services (CMS) said on April 21.
The continuation of the bridge program will ensure that beneficiaries keep having access to the drugs, known as GLP-1s, officials said in a memorandum.
The bridge program was set to wrap up at the end of 2026.
The interim coverage of the program will remain in place at the same time officials said they would not, at least for now, introduce a pilot program that would let Medicare directly negotiate with drugmakers to keep expenses down and involve Medicare insurers paying for GLP-1 drugs such as Wegovy….